NOD2: Nucleotide-binding oligomerization domain-containing protein 2
Pattern recognition receptor (PRR) that detects bacterial peptidoglycan fragments and other danger signals and plays an important role in gastrointestinal immunity.
- Drugs that act on it: 1
- Approved: 1
- In phases 1 to 3: 0
- Sponsors: 0
Who is on it, and how far along
Every drug ChEMBL records acting on NOD2, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Small molecule 1
| Drug | Furthest stage | Sponsor | Modality | Action | Open trials |
|---|---|---|---|---|---|
| Mifamurtide acid | Approved | — | Small molecule | OtherNucleotide-binding oligomerization domain-containing protein 2 other | 2 |
| Evaluation of the Safety and Efficacy of Mifamurtide Versus Standard Treatment With Sorafenib in Patients With High-risk Osteosarcoma | Mifamurtide acid | Phase 2 | Recruiting | Anna Raciborska | Aug 26, 2026 |
| Mifamurtide Combined With Post-operative Chemotherapy for Newly Diagnosed High Risk Osteosarcoma Patients | Mifamurtide acid | Phase 2 | Active, not recruiting | UNICANCER | Aug 22, 2018 |
- Blau syndrome0.85
- Inflammatory bowel disease 10.80
- Crohn disease0.77
- Yao syndrome0.69
- Inflammatory bowel disease0.58
- Enteritis0.51
- Behcet disease0.49
- Asthma0.49
- Childhood onset asthma0.47
- Oral ulcer0.43
- Small bowel Crohn disease0.42
- Respiratory system disorder0.42
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL1293266, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-22. Gene name, function (UniProt Q9HC29, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets